Fri, Jul 25, 2014, 12:43 PM EDT - U.S. Markets close in 3 hrs 17 mins


% | $
Click the to save as a favorite.

Seattle Genetics Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • atpl1959 atpl1959 Nov 9, 2012 2:34 PM Flag

    SGEN conference call highlights - 3Q 2012

    It couldn't have been any clearer that it is only the on label revenue that will remain flat, but all it takes is some reading of the upcoming ASH abstracts to show that significant label expansion will be a given in the not too distant future, especially with DLBCL and AITL.
    What will really make this company soar is another drug in the pipeline. Watch out for SGN-CD33A. Very impressive pre clinical data, especially when compared with the already FDA approved Mylorg for AML. Of course Mylotarg was ultimately withdrawn due to toxicity concerns, but the SGN-CD33A shows much more potent activity at much less dosage levels than with Mylorg.
    Another very interesting abstract from ASH is the potential use of Adcetris with epigenetic agents. Apparently these agents are able to deactivate the genes that are responsible for repressing CD 30 expression. This "de-repression" basically results in CD 30 expression and making the cancer amenable to Adcetris.
    Long and still very strong. Hey, Rituxin was only a 100M drug the first year of sales. It took 5 years to become a billion dollar drug. Now it's 2.5 B. This doesn't happen over night.
    Speaking of Rituxan, there was also a recent pilot study result combining Rit and Dacetuzumab, SGN 40, that showed excellant results in DLBCL. 47% ORR and quite a few CR's. Published in Sept.. Rebirth of SGN 40 for relapsed refractory NHL with Rituxin, and then Adcetris will handle all the CD 30 expressing DLBCLs, approx. 25% of all DLBCL.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • blackmenrock Nov 9, 2012 5:07 PM Flag

      I did not know of the sgn40 study. Thank you. I will look at that. I expected 40 to resurface as sgn45 as the naked antibody, like the 30, did not seem to have much anti-tumor activity. With SGEN's new linker and chemo 40 (or 45) could emerge as an excellent candidate in B-cell. Maybe better than the Roche 22 or 79. Let's hope.

34.62-0.07(-0.20%)12:42 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.